


Agenda



Defining, Achieving, and Maintaining Disease Control in Hypoparathyroid Patients

Vienna, September 29 – 30, 2017

Day 1 | Friday, September 29, 2017

Time	Topic	Speaker
8:30 – 8:40	Welcome	Wilfried G Alois Gessl (Austria)
	Meeting Objectives and Introduction	Jens Bollerslev (Norway) Maria Luisa Brandi (Italy) Michael Mannstadt (USA)
Session 1: The Patient with Hypoparathyroidism Co-chairs: Jens Bollerslev, Maria Luisa Brandi, Michael Mannstadt, Wilfried G Alois Gessl		
8:40 – 9:10	Keynote Presentation: Epidemiology, diverse etiologies and clinical phenotypes in hypoparathyroidism	Jens Bollerslev (Norway) Lars Rejnmark (Denmark)
9:10 – 9:30	Plenary Presentation: The burden of disease in hypoparathyroid patients: short- and long-term consequences	Maria Luisa Brandi (Italy)
9:35 – 11:00 <i>Attendees will participate in each of two workshops (40 minutes each, 5 minutes break between sessions)</i>	Workshop 1: Autoimmune hypoparathyroidism: case studies	Olle Kämpe (Sweden)
	Workshop 2: Post-surgical chronic hypoparathyroidism: case studies	Antonio Sitges-Serra (Spain) William Fraser (UK)
11:00 – 11:10	Coffee break	
Session 2: Defining Targets and Monitoring Outcomes in Patients with Hypoparathyroidism Co-chairs: Jens Bollerslev, Maria Luisa Brandi, Michael Mannstadt, Wilfried G Alois Gessl		
11:10 – 11:40	Keynote Presentation: Goals of treatment for the hypoparathyroid patient: current guidelines	Jens Bollerslev (Norway)
11:40 – 12:00	Plenary Presentation: Individualizing treatment with conventional agents	Claudio Marcocci (Italy)
12:05 – 13:30 <i>Attendees will participate in each of two workshops (40 minutes each, 5 minutes break between sessions)</i>	Workshop 3: Patient evaluation and setting treatment goals: case studies	Eric Fink Eriksen (Norway)
	Workshop 4: Monitoring patients with comorbidities: case studies	Östen Ljunggren (Sweden)
13:30 – 14:30	Lunch	

Agenda



Defining, Achieving, and Maintaining Disease Control in Hypoparathyroid Patients

Vienna, September 29 – 30, 2017

Day 1 | Friday, September 29, 2017

Session 3: Understanding Patient Burden: The Long-term Consequences of Chronic Hypoparathyroidism

Co-chairs: Jens Bollerslev, Maria Luisa Brandi, Michael Mannstadt

14:30 – 14:50	Plenary Presentation: Renal disease in the patient with hypoparathyroidism	Pascal Houillier (France)
14:50 – 15:10	Plenary Presentation: Neurologic consequences of hypoparathyroidism	Lars Rejnmark (Denmark)
15:10 – 15:30	Plenary Presentation: Bone metabolism and skeletal complications of hypoparathyroidism	John P Bilezikian (USA)
15:30 – 15:45	Coffee break	
15:50 – 16:20	Plenary Presentation: Managing the complications of hypoparathyroidism: cognitive dysfunction and psychiatric disease	David J Llewellyn (UK)
16:20 – 17:20	Guided Roundtable Discussion: Understanding patient burden: the long-term consequences of chronic hypoparathyroidism	Moderation: Claudio Marcocci (Italy) Discussants: Pascal Houillier (France) Lars Rejnmark (Denmark) John P Bilezikian (USA) David J Llewellyn (UK) Heide Siggelkow (Germany) Maria Luisa Brandi (Italy) William Fraser (UK)
17:20 – 17:40	Plenary Presentation: Impaired quality of life in hypoparathyroid patients	Heide Siggelkow (Germany)
17:40 – 17:50	Closing Day 1	Maria Luisa Brandi (Italy)

Agenda



Defining, Achieving, and Maintaining Disease Control in Hypoparathyroid Patients

Vienna, September 29 – 30, 2017

Day 2 | Saturday, September 30, 2017

Time	Topic	Speaker
8:45 – 8:50	Welcome and Objectives Day 2	Michael Mannstadt (USA)
Session 4: Treatment Goals and Therapies for Hypoparathyroidism Co-chairs: Jens Bollerslev, Maria Luisa Brandi, Michael Mannstadt		
8:50 – 9:20	Keynote Presentation: Treatment goals and therapies for hypoparathyroidism	Maria Luisa Brandi (Italy)
9:20 – 10:20	Guided Roundtable discussion: How to define control and lack of control of disease in hypoparathyroid patients?	Moderation: John P Bilezikian (USA) Discussants: Jens Bollerslev (Norway) Maria Luisa Brandi (Italy) Michael Mannstadt (USA)
10:20 – 10:40	Coffee break	
10:40 – 11:00	Plenary Presentation: Long-term outcomes with parathyroid hormone therapy	John P Bilezikian (USA)
11:00 – 12:00	Guided Roundtable discussion: Which patients may benefit from human recombinant parathyroid hormone?	Moderation: John P Bilezikian (USA) Discussants: Jens Bollerslev (Norway) Maria Luisa Brandi (Italy) Michael Mannstadt (USA)
12:00 – 12:40	Keynote presentation: How will hypoparathyroid patients be treated in the future?	Michael Mannstadt (USA)
12:40 – 12:55	Meeting closing	Jens Bollerslev (Norway)